[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367160-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367160-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-diagnostics-for-improved-treatment-of-gynecological-cancer","Novel diagnostics for improved treatment of gynecological cancer","","This review article summarizes efforts to develop novel biomarkers for diagnosis and screening of cervical, endometrial, and ovarian cancer, highlighting Uppsala research over the last 20 years. Sweden’s 1966 cervical screening program using cytology is discussed, along with progress toward self-sampling and primary human papillomavirus testing, plus preventive vaccines and improved management of cervical dysplasia. In contrast, efficient biomarkers for endometrial and ovarian cancer remain limited; proteomics-based plasma protein markers for adnexal ovarian masses and evaluations for endometrial biomarkers are described. Population screening requires careful cost-benefit analysis, potentially extending cervical screening to cover all three cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-diagnostics-for-improved-treatment-of-gynecological-cancer/367160/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-diagnostics-for-improved-treatment-of-gynecological-cancer/367160.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which gynecological cancers does the review focus on for new diagnostic biomarkers?","Question",{"text":63,"@type":64},"The review covers cervical, endometrial, and ovarian cancer, emphasizing biomarker development for diagnosis and screening.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What changes to cervical cancer screening does the paper discuss?",{"text":68,"@type":64},"It discusses moving from cytology-based screening to approaches that improve convenience and coverage, including self-sampling and using human papillomavirus as the primary test, along with vaccination and improved treatment for cervical dysplasia.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are population screening programs for ovarian and endometrial cancer described as challenging?",{"text":72,"@type":64},"Efficient biomarkers for endometrial and ovarian cancer are still lacking, and ovarian cancer screening is limited by the absence of biomarkers with sufficient sensitivity and specificity to justify screening.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367160,1790583065,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","REVIEW ARTICLE  \nNovel diagnostics for improved treatment of gynecological cancer  \nUlf Gyllensten  \nDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden  \nABSTRACT  \nThis paper summarizes the efforts to develop novel biomarkers for diagnosis and screening of the three main gynecological cancers, cervical, endometrial, and ovarian cancer, with an emphasis on research performed during the last 20 years in Uppsala. A cervical cancer screening program has existed in Sweden since 1966 using cytology as the primary test. Over the last two decades, research has provided the scientific base for a transition to self-sampling to improve convenience of the woman and achieve higher population coverage, and use of human papillomavirus as the primary test. Also, efficient prophylactic vaccines and more efficient treatment strategies of women with cervical dysplasia have been introduced. Together, these medical tools have the potential to eradicate cervical cancer by 2120, as envisaged by WHO. By contrast, efficient biomarkers for endometrial and ovarian cancer are still lacking. Through the use of high-throughput proteomics, we have identified novel plasma protein biomarkers to be used in the diagnosis of women with adnexal ovarian mass upon transvaginal ultrasound, and possibly also for early detection in population screening. Similarly, novel biomarkers for the diagnosis of endometrial cancer are being evaluated. To establish a population-based screening program requires careful cost-benefit analyses. One alternative would be to broaden the focus of the current cervical cancer screening program to include also the novel biomarkers for ovarian and  \nendometrial cancer, and thereby achieve screening for all three gynecological cancers. A program that screens for all three diseases could increase motivation to participate and thereby population coverage.  \nARTICLE HISTORY  \nReceived: 7 January 2025  \nAccepted: 7 January 2025  \nPublished: 13 February 2025  \nKEYWORDS  \nGynecological cancer; cervical cancer; ovarian cancer; endometrial cancer; proteomics; biomarkers  \nProfessor Ulf Gyllensten, winner of the Medical Faculty of Uppsala University Rudbeck Award 2024.  \nBackground  \nGynecological cancer, including cervical, endometrial, and ovarian cancer, represents a significant global health challenge, impacting millions of women each year. Cervical cancer, caused by persistent infection with oncogenic forms of human papillomavirus (HPV), is the fourth most common cancer among women worldwide. In 2022, an estimated 660,000 new cases of cervical cancer were diagnosed, and approximately 350,000 women lost their lives to this preventable disease (1) . Endometrial cancer is the most common malignancy of the uterus, and also a growing concern, with approximately 420,000 new cases reported globally in 2022 (2) . This cancer predominantly affects postmenopausal women and has been linked to factors such as obesity, hormone replacement therapy, and metabolic syndrome. While survival rates are generally favorable when endometrial cancer is detected early, the increasing prevalence of obesity worldwide has contributed to arise in the number of cases. Present efforts to address endometrial cancer include promoting a healthy lifestyle,  \nCONTACT Ulf Gyllensten  [ulf.gyllensten@igp.uu.se](ulf.gyllensten@igp.uu.se)[ ](ulf.gyllensten@igp.uu.se)© 2025 The Author(s). Published by Upsala Medical Society.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \n2 U. GYLLENSTEN  \nimproving early detection through awareness and advancing treatment options for more aggressive forms of the disease.  \nOvarian cancer, often referred to as the ‘silent killer’ due to its subtl","cbCailD8wZpEWRdk","https://ap.wps.com/l/cbCailD8wZpEWRdk","pdf",322714,"English","# Abstract\n# Background\n# Cervical cancer – from etiology to screening and vaccination","[{\"question\":\"Which gynecological cancers does the review focus on for new diagnostic biomarkers?\",\"answer\":\"The review covers cervical, endometrial, and ovarian cancer, emphasizing biomarker development for diagnosis and screening.\"},{\"question\":\"What changes to cervical cancer screening does the paper discuss?\",\"answer\":\"It discusses moving from cytology-based screening to approaches that improve convenience and coverage, including self-sampling and using human papillomavirus as the primary test, along with vaccination and improved treatment for cervical dysplasia.\"},{\"question\":\"Why are population screening programs for ovarian and endometrial cancer described as challenging?\",\"answer\":\"Efficient biomarkers for endometrial and ovarian cancer are still lacking, and ovarian cancer screening is limited by the absence of biomarkers with sufficient sensitivity and specificity to justify screening.\"}]","Novel diagnostics for improved treatment of gynecological cancer | PDF",1790169540,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f57655f5ad64577d4bb125404cd9c27a.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b23415720a9379476e28ffdf55b825c.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19a9a46c5b9fff669db888b60aa217d2.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e2d6b675cba9211495f608f50bbbebe.webp",980,1276]